OPNT Opiant Pharmaceuticals Inc

Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/opnt) is investigating potential claims against the board of directors of OPNET Technologies, Inc. (“OPNET” or the “Company”) (NASDAQ: OPNT) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to Riverbed Technology in a transaction valued at approximately $989 million.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of OPNET. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/opnt

Under the terms of the proposed transaction, OPNET shareholders will receive a fixed 0.2774 shares of Riverbed common stock plus $36.55 in cash in exchange for each share of OPNET ordinary stock.

If you own shares of OPNET and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/opnt. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024